OBJECTIVES: Our purpose was to determine whether geriatric assessments are associated with completion of a chemotherapy course, grade III/IV toxicity or survival in older adults with cancer. MATERIALS AND METHODS: In this prospective cohort study, patients aged 65 years and older with colorectal, lung, or breast cancer or lymphoma completed a brief geriatric assessment prior to chemotherapy. Endpoints included completion of the planned number of chemotherapy cycles, grade III/IV toxicity and survival. Multivariate logistic regression determined which factors were independently associated with completion of therapy, grade III/IV toxicity or death. RESULTS: Sixty-five patients were enrolled in the study. The median age was 73 years (range 65–89). Geriatric syndromes were common, including depression (21.5%), dependence on others to carry out instrumental activities of daily living (38.5%) and activities of daily living (10.8%), and comorbidities (mild 47.7%, moderate 20%, severe 15.4%). Of the 65 participants, 67.6%completed the planned number of chemotherapy cycles. Curative intent therapy [OR 4.97 (95% CI 1.21–18.81)], Eastern Cooperative Oncology Group (ECOG) performance status 2–3 [OR 0.089 (0.015–0.53)] and renal function [OR 1.03 (1.00–1.06) per ml/min] were significantly associated with therapy completion. Furthermore, 31.1% experienced grade III/IV nonhematologic toxicity. Moderate to severe comorbidities significantly increased the risk of grade III/IV non-hematologic toxicity [OR 6.13 (1.65–22.74)]. Patients who received chemotherapy with curative intent had lower mortality [HR 0.15 (0.06–0.42)], while patients who reported a fall in themonth prior to chemotherapy had an increased risk of death [HR 3.20 (1.13–9.11)]. CONCLUSIONS: Geriatric assessment is associatedwith completion of a planned number of cycles of chemotherapy, grade III/IV non-hematologic toxicity, and mortality.
OBJECTIVES: Our purpose was to determine whether geriatric assessments are associated with completion of a chemotherapy course, grade III/IV toxicity or survival in older adults with cancer. MATERIALS AND METHODS: In this prospective cohort study, patients aged 65 years and older with colorectal, lung, or breast cancer or lymphoma completed a brief geriatric assessment prior to chemotherapy. Endpoints included completion of the planned number of chemotherapy cycles, grade III/IV toxicity and survival. Multivariate logistic regression determined which factors were independently associated with completion of therapy, grade III/IV toxicity or death. RESULTS: Sixty-five patients were enrolled in the study. The median age was 73 years (range 65–89). Geriatric syndromes were common, including depression (21.5%), dependence on others to carry out instrumental activities of daily living (38.5%) and activities of daily living (10.8%), and comorbidities (mild 47.7%, moderate 20%, severe 15.4%). Of the 65 participants, 67.6%completed the planned number of chemotherapy cycles. Curative intent therapy [OR 4.97 (95% CI 1.21–18.81)], Eastern Cooperative Oncology Group (ECOG) performance status 2–3 [OR 0.089 (0.015–0.53)] and renal function [OR 1.03 (1.00–1.06) per ml/min] were significantly associated with therapy completion. Furthermore, 31.1% experienced grade III/IV nonhematologic toxicity. Moderate to severe comorbidities significantly increased the risk of grade III/IV non-hematologic toxicity [OR 6.13 (1.65–22.74)]. Patients who received chemotherapy with curative intent had lower mortality [HR 0.15 (0.06–0.42)], while patients who reported a fall in themonth prior to chemotherapy had an increased risk of death [HR 3.20 (1.13–9.11)]. CONCLUSIONS: Geriatric assessment is associatedwith completion of a planned number of cycles of chemotherapy, grade III/IV non-hematologic toxicity, and mortality.
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: G Freyer; J-F Geay; S Touzet; J Provencal; B Weber; J-P Jacquin; G Ganem; N Tubiana-Mathieu; O Gisserot; E Pujade-Lauraine Journal: Ann Oncol Date: 2005-08-10 Impact factor: 32.976
Authors: Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: Ruth E Hubbard; M Sinead O'Mahony; George M Savva; Brian L Calver; Ken W Woodhouse Journal: J Cell Mol Med Date: 2009-03-06 Impact factor: 5.310
Authors: Arti Hurria; M Suzette Blanchard; Timothy W Synold; Joanne Mortimer; Cathie T Chung; Thehang Luu; Vani Katheria; Arnold J Rotter; Carol Wong; Anthony Choi; Tao Feng; Rupal Ramani; Caroline M Doan; Jaycen Brown; George Somlo Journal: Oncologist Date: 2014-12-09
Authors: Leslie Y Chiang; Jingxia Liu; Kellie L Flood; Maria B Carroll; Jay F Piccirillo; Susan Stark; Adam Wang; Tanya M Wildes Journal: J Geriatr Oncol Date: 2015-05-11 Impact factor: 3.599
Authors: M F Barginear; H Muss; G Kimmick; C Owusu; E Mrozek; A Shahrokni; K Ballman; A Hurria Journal: Breast Cancer Res Treat Date: 2014-05-22 Impact factor: 4.872
Authors: Clark Dumontier; Kerri M Clough-Gorr; Rebecca A Silliman; Andreas E Stuck; André Moser Journal: J Geriatr Oncol Date: 2016-12-13 Impact factor: 3.599
Authors: Tanya M Wildes; Priya Dua; Susan A Fowler; J Philip Miller; Christopher R Carpenter; Michael S Avidan; Susan Stark Journal: J Geriatr Oncol Date: 2014-10-30 Impact factor: 3.599